Enhabit (EHAB) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
7 May, 2026Executive summary
Net service revenue rose 1.9% year-over-year to $264.8 million for Q1 2026, driven by 6.2% growth in Hospice and 0.6% in Home Health.
Net income attributable to shareholders increased 7.9% to $19.2 million, with EPS at $0.37 (basic) and $0.36 (diluted).
A merger agreement was signed in February 2026; closing is expected in Q2 2026, after which shares will be delisted.
No branch closures occurred in Q1 2026, and none are anticipated for the remainder of the year.
Financial highlights
Gross margin was $130.6 million, up 0.7% year-over-year.
General and administrative expenses fell 10.0% to $96.7 million, aided by a $17.7 million litigation settlement gain.
Adjusted EBITDA was $24.4 million, down from $26.6 million in Q1 2025.
Operating income increased 84.3% to $29.3 million, reflecting lower G&A expenses.
Effective tax rate dropped to 13.5% from 28.7% due to changes in valuation allowance.
Outlook and guidance
The proposed 2027 Hospice Rule would increase payments by 2.4% starting October 2026, expected to benefit revenue.
Management expects continued compliance with debt covenants but notes ongoing monitoring is required.
Latest events from Enhabit
- Shareholders to vote on $13.80 per share cash merger, with board unanimous in support.EHAB
Proxy filing14 Apr 2026 - Shareholders to vote on a $13.80/share cash merger, with board unanimous support and appraisal rights.EHAB
Proxy filing30 Mar 2026 - Pending merger with Kinderhook Industries follows a year of revenue growth and operational improvement.EHAB
Proxy Filing5 Mar 2026 - Revenue and EBITDA rose, leverage fell, and a merger is pending.EHAB
Q4 20255 Mar 2026 - Acquisition by Kinderhook Industries prompts shareholder vote and transition to private ownership.EHAB
Proxy Filing26 Feb 2026 - Kinderhook Industries to acquire Enhabit; shareholders to receive $13.80 per share upon closing.EHAB
Proxy Filing23 Feb 2026 - Pending acquisition will take the company private, subject to shareholder approval in 2026.EHAB
Proxy Filing23 Feb 2026 - Stockholders to receive $13.80 per share in a $1.1B buyout, pending approvals.EHAB
Proxy Filing23 Feb 2026 - Adjusted EBITDA rose 5.4% as non-Medicare admissions and hospice growth offset revenue softness.EHAB
Q2 20242 Feb 2026